Phase II Study of Gleevec (Imatinib Mesylate) in Patients With Idiopathic Hypereosinophilic Syndrome (HES).
Withdrawn prior to enrolment
Phase of Trial: Phase II
Latest Information Update: 08 Jan 2016
At a glance
- Drugs Imatinib (Primary)
- Indications Hypereosinophilic syndrome
- Focus Therapeutic Use
- 12 Apr 2011 Status changed from active, no longer recruiting to withdrawn prior to recruitment as reported by ClinicalTrials.gov.
- 18 May 2010 New trial record